Frontlight ResearchEarly access
CompletedNo phase
Assessing Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Secukinumab.
Key facts
- Who runs it
- Novartis Pharmaceuticals
- Where
- United Arab Emirates4 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 63 people enrolled
- Started
- 28 Apr 2025
- Ended
- 16 Jul 2026
- Type of study
- Observational
- Treatments tested
- Secukinumab
- Record updated
- 12 November 2026
Who can take part
- Age
- 18 years to 99 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Patient with a confirmed diagnosis of active moderate to severe HS (Hurley Score 2-3)
- Male or Female adult patients ≥ 18 years of age at the time of data collection
- Patient newly initiated on Secukinumab (first dose to coincide within 1 month of the signature of the informed consent)
- Patients with a diagnosis of HS who are currently using antibiotics/ have undergone surgery or not as part of their routine clinical management are eligible for inclusion
- Patients with a diagnosis of HS who have a history of previous treatment with Adalimumab or any other anti-TNF agent as part of their routine clinical management or biologic naïve are eligible for inclusion
- Agreed to sign an informed consent to be able to fill in the questionnaires
Who cannot take part
- Patients not fulfilling any of the abovementioned inclusion criteria
- Patient's refusal to be included in the study or refusal to sign the informed consent
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study will be conducted to address the lack of concrete data on the impact of pharmaceutical intervention on short-term patient satisfaction and quality of life (QoL) in patients with Hidradenitis Suppurativa (HS) in real-world settings, especially in the Gulf Region.
The group in the trial
- Secukinumab
Patients who are newly initiated on treatment with Secukinumab
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Assessing Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Secukinumab in Routine Clinical Practice in the United Arab Emirates: ILLUMINATE-HS, a Prospective Patient Surve
- Record updated
- 12 November 2026